Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

3ZXE

Crystal structure of Human Galectin-7 in complex with a galactose- benzylphosphate inhibitor

Summary for 3ZXE
Entry DOI10.2210/pdb3zxe/pdb
Related1BKZ 2GAL 3GAL 3ZXF 4GAL 5GAL
DescriptorGALECTIN-7, METHYL 2-O-[(S)-(BENZYLOXY)(HYDROXY)PHOSPHORYL]-3-DEOXY-3-{[(4-METHYLPHENYL)CARBONYL]AMINO}-1-THIO-BETA-D-GALACTOPYRANOSIDE (3 entities in total)
Functional Keywordssugar binding protein
Biological sourceHOMO SAPIENS (HUMAN)
Cellular locationCytoplasm: P47929
Total number of polymer chains2
Total formula weight30524.33
Authors
Masuyer, G.,Oberg, C.T.,Leffler, H.,Nilsson, U.J.,Acharya, K.R. (deposition date: 2011-08-10, release date: 2011-11-30, Last modification date: 2023-12-20)
Primary citationMasuyer, G.,Jabeen, T.,Oberg, C.T.,Leffler, H.,Nilsson, U.J.,Acharya, K.R.
Inhibition Mechanism of Human Galectin-7 by a Novel Galactose-Benzylphosphate Inhibitor.
FEBS J., 279:193-, 2012
Cited by
PubMed Abstract: Galectins are involved in many cellular processes due to their ability to bind carbohydrates. Understanding their functions has shown the necessity for potent and specific galectin inhibitors. Human galectin-7 (hGal-7), in particular, has been highlighted as an important marker in many types of cancer by either inhibiting or promoting tumour growth. Producing ligands able to selectively target hGal-7 will offer promising tools for deciphering cancer processes in which hGal-7 is involved as well as present potential solutions for future therapeutics. Here we report the high resolution crystal structure of hGal-7 in complex with a synthetic 2-O-benzylphosphate-galactoside inhibitor (which is > 60-fold more potent than its parent galactoside). The high resolution crystallographic analysis highlights the validity of using saccharide derivatives, conserving properties of the galactose binding, while enhanced affinity and specificity is provided by the added phosphate group. This structural information will allow the design of further inhibitors with improved potency and specificity.
PubMed: 22059385
DOI: 10.1111/J.1742-4658.2011.08414.X
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.67 Å)
Structure validation

226707

건을2024-10-30부터공개중

PDB statisticsPDBj update infoContact PDBjnumon